Abstract
Misfolding, polymerization, and defective secretion of functional alpha-1 antitrypsin underlies the predisposition to severe liver and lung disease in alpha-1 antitrypsin deficiency. We have identified a novel (Ala336Pro, Baghdad) deficiency variant and characterized it relative to the wild-type (M) and Glu342Lys (Z) alleles. The index case is a homozygous individual of consanguineous parentage, with levels of circulating alpha-1 antitrypsin in the moderate deficiency range, but is a biochemical phenotype that could not be classified by standard methods. The majority of the protein was present as functionally inactive polymer, and the remaining monomer was 37% active relative to the wild-type protein. These factors combined indicate an 85 to 95% functional deficiency, similar to that seen with ZZ homozygotes. Biochemical, biophysical, and computational studies further defined the molecular basis of this deficiency. These studies demonstrated that native Ala336Pro alpha-1 antitrypsin could populate the polymerogenic intermediate—and therefore polymerize—more readily than either wild-type alpha-1 antitrypsin or the Z variant. In contrast, folding was far less impaired in Ala336Pro alpha-1 antitrypsin than in the Z variant. The data are consistent with a disparate contribution by the “breach” region and “shutter” region of strand 5A to folding and polymerization mechanisms. Moreover, the findings demonstrate that, in these variants, folding efficiency does not correlate directly with the tendency to polymerize in vitro or in vivo. They therefore differentiate generalized misfolding from polymerization tendencies in missense variants of alpha-1 antitrypsin. Clinically, they further support the need to quantify loss-of-function in alpha-1 antitrypsin deficiency to individualize patient care.
Keywords: alpha-1 antitrypsin deficiency, polymerization, mutation, unfolding, serpinopathies
Clinical Relevance
We report a novel mutant of the plasma protease inhibitor alpha-1 antitrypsin, from which we (1) note a fundamental discrepancy between the standard measure of severity of antitrypsin deficiency and the true functional capacity of the protein, (2) find this variant misfolds less yet self-associates more readily than the severe Z mutant and pinpoint the steps of the polymerization pathway where these differences occur, and (3) distinguish the importance of the site of the mutation for stability and function from that of the Z mutant. This study highlights the symbiosis between the clinical and academic setting that can significantly impact patient care.
Alpha-1 antitrypsin is produced in the liver, circulates as the most abundant antiprotease, and critically regulates activity of neutrophil elastase and proteinase-3 in the lung. Its mechanism of action involves a transition from a metastable native state with a five-stranded central β-sheet to a thermodynamically favored six-stranded central β-sheet conformation. This metastability is subverted by pathogenic mutations in alpha-1 antitrypsin deficiency, one of the most common hereditary disorders. Over 120 mutations in the SERPINA1 gene encoding alpha-1 antitrypsin have been identified, with approximately 80 implicated in disease pathogenesis, indicative of a highly polymorphic gene (1). Current screening involves quantification of circulating levels, with M (wild-type; ATM) homozygotes (PiMM) ranging between 1.0 and 2.8 g/liter of alpha-1 antitrypsin (2); clinically relevant deficiency is considered when levels are ≤0.5 g/liter. Isoelectric focusing of the plasma protein identifies variants by their migration patterns (3). Around 95% of clinically significant deficiency is caused by the Z (Glu342Lys; ATZ) pathogenic variant. Approximately 1 in 1,600 individuals in populations of North European descent are homozygous for this allele (PiZZ), and in these individuals plasma levels are ≤0.2 g/liter (4, 5). Misfolding of the Z alpha-1 antitrypsin polypeptide chain results in degradation (6) but is also associated with accumulation of alpha-1 antitrypsin molecules that have undergone aberrant stabilization through ordered self-association (polymerization). Polymers have a “beads-on-a-string” appearance when viewed by electron microscopy (7) and are sequestered within inclusions in the endoplasmic reticulum of hepatocytes (8). Polymerization is associated with toxic gain-of-function and so predisposes to neonatal hepatitis, cirrhosis, and hepatocellular carcinoma (9). The lack of circulating inhibitor permits excessive pulmonary inflammation and uncontrolled proteolytic degradation of lung parenchyma and hence severe panlobular emphysema, particularly in the context of smoking (10). These loss-of-function effects may be further aggravated by functional inactivation of alpha-1 antitrypsin by oxidative stress and polymerization of circulating protein (8, 11).
Alpha-1 antitrypsin adopts the conserved fold that is a hallmark of the serpin superfamily (12), comprising three β-sheets (A–C), nine α-helices (A–I), and a reactive center loop (RCL) bait sequence that acts as a pseudo-substrate for the target protease (Figure 1A, left). Structural lability of the central β-sheet A is required for inhibitor function but is also key to formation of ordered polymers. Here we describe a novel mutation affecting a central residue in β-sheet A, Ala336Pro, in a homozygous individual exhibiting a moderate deficiency of circulating alpha-1 antitrypsin. The novel variant (alpha-1 antitrypsin Baghdad; ATA336P) has been investigated using immunological and biophysical approaches. The results show the individual to have a severe functional deficiency far beyond the reduction in plasma levels and that the homozygous state therefore confers comparable emphysema risk to that of PiZZ individuals. Additionally, the mutant provides mechanistic insight into the role of strand 5 of β-sheet A in the formation of the intermediate and subsequent steps in alpha-1 antitrypsin polymerization and the relationship between misfolding and polymerization.
Materials and Methods
Purification of Alpha-1 Antitrypsin and Preparation of Conformers
Alpha-1 antitrypsin was purified from human plasma using Alpha Select resin followed by Q Sepharose chromatography (GE Healthcare, Little Chalfont, UK) and stored in PBS, 5% vol/vol glycerol, and 0.17% vol/vol β-mercaptoethanol at −80°C. Wild-type (ATM) protein purified in this way was indistinguishable from that obtained using previously published methods (13) when assessed by inhibitory activity, intrinsic tryptophan fluorescence, circular dichroism spectra, or LC/MS (14).
Gel Electrophoresis and Western Blot Analysis
Plasma samples, diluted 1:100, were resolved by nondenaturing PAGE (Life Technologies, Paisley, UK) and transferred onto a PVDF membrane. Primary incubation was with the 2C1 antibody that specifically recognizes alpha-1 antitrypsin polymers (9) or a non-conformationally selective rabbit polyclonal antibody against alpha-1 antitrypsin. The membrane was then washed and incubated with IR680RD anti-mouse or IR800CW anti-rabbit secondary antibodies with visualization using an Odyssey imaging system (LiCOR, Cambridge, UK). All densitometry was performed using ImageJ (15). Urea Tris-Glycine gels (8% wt/vol) were produced using an SDS-free Laemmli system (16) with the addition of urea to 6 M.
Assessment of Proteinase Inhibition
The stoichiometry of inhibition (SI) and association rate constant of alpha-1 antitrypsin (kass) were assessed at 25°C using bovine α-chymotrypsin as described previously (17). The ability to form an enzyme-inhibitor complex was assessed by incubating differing concentrations of protease with alpha-1 antitrypsin and resolution (without heating) by SDS-PAGE.
Spectral Studies
Far-UV circular dichroism spectra were collected using a Jasco J-810 spectropolarimeter (Dunmow, UK) as described previously (17). Intrinsic fluorescence spectra (emission, 300–400 nm) were collected using a Perkin Elmer LS50B spectrofluorimeter (Coventry, UK)(excitation, 280 nm; scan, 500 nm/s; 10 accumulations; 5-nm slits). The center of spectral mass (COSM) was calculated as a weighted average, with the intensity at each wavelength weighted by the wavenumber 1/λ. Bis-ANS (4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid) spectra (excitation, 370 nm; emission, 400–600 nm) were collected after a 2-minute incubation of 10 μM dye with 2 μM alpha-1 antitrypsin in PBS.
Molecular Modeling
The mutation was modeled against the wild-type structure (1QLP [18]) using VMD (19) and NAMD (20) as described in the online supplement.
Thermal Denaturation
The transition to the polymerization intermediate was monitored using a SYPRO Orange–based thermal denaturation assay as described previously (17) using various rates of temperature increase.
Polymerization Kinetics Monitored by Förster Resonance Energy Transfer
The Cys232 residue of alpha-1 antitrypsin was labeled with Alexa Fluor 488 (AF488) maleimide and Alexa Fluor 594 (AF594) maleimide (Life Technologies). Polymerization was monitored as the increase in acceptor (AF594) fluorescence at 615 nm with excitation of donor (AF488) at 470 nm using a Mastercycler realplex4 instrument (Eppendorf, Stevenage, UK) as described (17, 21, 22).
Equilibrium Unfolding/Dilution Refolding
Unfolding curves were obtained by incubating alpha-1 antitrypsin with guanidinium hydrochloride for 3 hours at room temperature before recording intrinsic fluorescence spectra as described above. Derived COSM values were fitted to a three-state unfolding model (23). Refolding involved denaturing a 10 mg/ml stock of alpha-1 antitrypsin overnight at 4°C in 6 M guanidinium hydrochloride followed by rapid dilution into PBS containing 5% vol/vol glycerol to 0.05 mg/ml and resolution on a 3 to 12% wt/vol nondenaturing gel.
Results
Clinical Case
A 41-year-old female never-smoker of Iraqi origin was referred to the London Alpha-1 Antitrypsin Deficiency Service after her serum alpha-1 antitrypsin levels were measured at 0.4 g/liter (normal range, 1.0–2.8 g/liter). She had been investigated for an ulnar neuropathy that resolved spontaneously. Family history revealed that her parents were first cousins. She reported no symptoms associated with alpha-1 antitrypsin deficiency. She was married to a third cousin with whom she had two children who are both alive and well. Isoelectric focusing phenotyping of circulating alpha-1 antitrypsin repeatedly produced an “unclear result” (see Figure E1A in the online supplement). Standard liver function tests (including bilirubin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, and γ-glutamyl transferase) were normal, albumin levels were marginally elevated, and there were no abnormalities on hepatic imaging by ultrasound or fibroscan. Lung function tests, including spirometry and gas transfer indices, were also normal. There was no abnormality of circulating antineutrophil cytoplasmic antibody. In view of the circulating deficiency and unclear phenotyping, SERPINA1 genotyping was undertaken and identified homozygosity for a nonsynonymous G1078C mutation, resulting in an Ala336Pro substitution that has not previously been described. This novel variant was named alpha-1 antitrypsin Baghdad (here also referred to as ATA336P) after the birthplace of the index case.
Ala336Pro Mutation Occurs in a Hot-Spot for Polymerogenic Mutants and Results in Substantial Polymerization In Vivo
Ala336 is located centrally to strand 5 of β-sheet A (strand 5A, s5A) in alpha-1 antitrypsin in a region known as the “shutter” (24) with a side-chain directed into the interior of the protein (Figure 1A, left panels). Residues within this region are known to regulate the opening of β-sheet A for incorporation of the reactive center loop as a neighboring strand (s4A) (25). Therefore, mutations in these residues can affect functional activity and the propensity to polymerize (24). In particular, in the native conformation, Ala336 packs against Phe51, whose interactions contribute to the sheet-opening mechanism (26). Mutations at adjacent sites (Figure E1B) result in highly polymerogenic variants of alpha-1 antitrypsin: Siiyama, Ser53Pro (27); Mmalton, Phe51del (28); and King’s, His 336Asp (9). Accordingly, Western blot analysis of patient plasma, separated by nondenaturing PAGE, indicated that the Baghdad variant was predominantly circulating as polymers that were recognized by the 2C1 monoclonal antibody. This indicates the Ala336Pro mutation results in polymers that share an epitope with pathological polymers of the Z variant that are observed in vivo (Figure 1B, right).
Ala336Pro Mutation Reduces the Inhibitory Activity of Alpha-1 Antitrypsin
Monomeric ATA336P alpha-1 antitrypsin was purified from plasma and was found to require a 2.7-fold greater stoichiometric excess (SI) over a model protease (α-chymotrypsin) than ATM to achieve full inhibition (Table 1; Figure 1C). This reduction in activity is greater than that observed for ATZ and will increase the unproductive turnover of inhibitor, resulting in the release of RCL-cleaved serpin and active protease. This was confirmed by SDS-PAGE analysis of the interaction with α-chymotrypsin at twice the stoichiometry of inhibitor-to-enzyme. Consistent with the kinetic experiments, the amount of alpha-1 antitrypsin that formed a complex with α-chymotrypsin relative to the cleaved, noncomplexed protein was lower for ATA336P than for ATZ (Figure E1C). In addition to this decrease in the efficiency of protease inhibition due to increased unproductive turnover, the Ala336Pro mutation also reduced the rate of the interaction: the association rate constant (kass) was 13% that of ATM (Table 1), lower than observed for Z alpha-1 antitrypsin (53% of ATM). This suggests a suboptimal RCL conformation for the encounter between alpha-1 antitrypsin and target protease. These deficits, together with the reduction in circulating levels, equates to a predicted in situ inhibitory rate that is two orders of magnitude slower for an Ala336Pro alpha-1 antitrypsin homozygote than for an M alpha-1 antitrypsin homozygote. This is comparable with the functional deficiency in Z alpha-1 antitrypsin homozygotes (Table 1). In practice, these values will significantly underestimate the loss-of-function for the deficiency variants because they do not account for the further reductions due to the proportion of alpha-1 antitrypsin circulating as functionally inactive polymers.
Table 1.
Variant | SI* | kass (M/s) | kass·SI (M/s) | Notional Rate† (%) |
---|---|---|---|---|
ATM | 1.0 | 2.65 ± 0.13 × 105 | 2.65 × 105 | 100 |
ATZ | 1.5 | 0.93 ± 0.10 × 105 | 1.40 × 105 | 3.5 |
ATA336P | 2.7 | 0.13 ± 0.03 × 105 | 0.35 × 105 | 1.0 |
Definition of abbreviations: ATA336P, alpha-1 antitrypsin Ala336Pro (Baghdad variant); ATM, wild-type alpha-1 antitrypsin (M variant); ATZ, alpha-1 antitrypsin Glu342Lys (Z variant); kass, association rate constant; SI, stoichiometries of inhibition.
Standard errors were <5% (calculated from three independent experiments).
Calculated as the rate of inhibition (per s) relative to ATM at a typical concentration (2, 0.2, and 0.4 mg/ml for ATM, ATZ, and ATA336P, respectively) if this were entirely circulating as native monomer.
The Proline Substitution Destabilizes β-Sheet A by Disrupting Strand 5A-6A Hydrogen Bonds
The alanine-to-proline change represents a substitution that is predicted to alter local structure. Although a bulkier side-chain may have some effect, it is an inherent restriction of backbone conformation that is expected to exert the greatest influence; proline residues are known to act as “strand-breakers” by disrupting the periodicity of the backbone angles inherent in these structural elements. To investigate the possibility of significant loss of secondary structure, circular dichroism spectra were recorded in the far-UV range. The substantially similar profile indicated a lack of change to the overall protein secondary structure and thus a globally intact protein (Figure 2A). However, differences were observed in the intrinsic tryptophan fluorescence spectrum of ATA336P (Figure 2B). In alpha-1 antitrypsin, the two tryptophan residues (Trp194 and Trp238) dominate the fluorescence profile, reporting changes in the breach region at the top of β-sheet A between s5A and s3A and β-sheet B, respectively (29). The intensity of the ATA336P spectrum was found to be intermediate between that of ATM and ATZ variants, with a “red-shift” of the peak maximum in common with ATZ. By analogy with ATZ, this is highly likely to reflect differences in side-chain arrangements and an altered dynamic behavior that increases average solvent exposure in the vicinity of the breach of β-sheet A (30). This region is the site of the proximal (N-terminal) hinge of the RCL, and the compromised kass value noted for ATA336P suggests the altered dynamics increase the proportion of molecules at a given time point with incompatible presentation of the protease recognition site. The environment-sensitive dye bis-ANS reports the presence of a hydrophobic binding site, which coincides with the transition to a polymerization intermediate (31). This dye displays enhanced fluorescence in the presence of the ATZ mutant (30) and yielded a comparable increase in ATA336P fluorescence over that of ATM (Figure 2C), consistent with an increased population of the intermediate state.
The structural consequences of the Ala336Pro mutation on the conformation of the protein were investigated in silico using NAMD (20) and VMD (19) packages. In the resulting model, the constraints imposed by the pyrrolidine ring of Pro336 do not disrupt strand 5A, consistent with a subset of backbone angles favored by proline residues that coincide with the β-sheet region of the Ramachandran plot. Indeed, it has been noted that proline residues can be accommodated in regions of a β-sheet that tolerate the disruption of the periodic main-chain hydrogen bonding, such as β-sheet edge strands (32). Consistent with this “edge-strand-effect,” the model predicts loss of two hydrogen bonds between strands 5A and 6A, which partly disrupts the neighboring s6A backbone conformation (Figure 1A, right panels; Figures E1D and E1E). The s6A-helix I-s5A sequence forms a contiguous structural unit that abuts the site of RCL incorporation during conformational change, parts of which show enhanced exchange properties with the solvent in ATZ (33). The effects on inhibitory activity suggest that the resulting reduction in β-sheet A stability is associated with changes in the conformational behavior of the RCL.
The Native State Is Less Stable in the Mutant than in Wild-Type
The center of spectral mass (COSM), calculated from intrinsic fluorescence of alpha-1 antitrypsin under pseudo-equilibrium denaturing conditions, reflects changes in solvent exposure predominantly of Trp194 at low concentrations with an increasing contribution from Trp238 at higher concentrations (30). It thus largely represents a probe of breach conformational stability, which follows a three-state unfolding pathway (34) that can be summarized as follows:
Support for the scheme proposed here comes from similar red-shifted intrinsic spectral (30) and bis-ANS binding (34) properties for the M and Z alpha-1 antitrypsin variants in unfolding intermediate-inducing concentrations of denaturant (30).
Intrinsic protein fluorescence spectra were collected during pseudo-equilibrium unfolding of the three variants, and COSM values were calculated. The resulting data were well described by a three-state equation (Figure 3A). The shapes of the plots show that an exposure of Trp194 characteristic of the intermediate state are already adopted by ATZ. Native ATA336P was found to be juxtaposed between ATM and ATZ, indicating the dynamic equilibrium shifted toward increased solvent exposure in the vicinity of the breach. The unfolding intermediates of ATM and ATA336P adopted a native Z-like COSM value, with the midpoints of the transitions indicating that ATA336P adopts this state at a lower denaturant concentration than ATM (Table 2). In contrast, the transition to the unfolded state was slightly earlier in ATA336P than the other two variants. Together these data support a continued role for central strand 5A interactions in the denaturant-induced ATM intermediate as it adopts Z-like dynamic behavior in the breach.
Table 2.
Variant | Midpoint* (GdnHCl M) |
|
---|---|---|
N→I | I→U | |
ATM | 0.94 ± 0.03 | 2.43 ± 0.03 |
ATZ | 1.33 ± 0.09 | 2.43 ± 0.06 |
ATAla336Pro | 0.42 ± 0.04 | 2.27 ± 0.03 |
Definition of abbreviations: ATA336Pro, alpha-1 antitrypsin Ala336Pro (Baghdad variant); ATM, wild-type alpha-1 antitrypsin (M variant); ATZ, alpha-1 antitrypsin Glu342Lys (Z variant); GdnHCl, guanidium hydrochloride; I, intermediate; M, units of concentration in molar; N, native; U, unfolded states of alpha-1 antitrypsin.
The midpoints of denaturation (in guanidium hydrochloride) were obtained by fitting a function describing three-state unfolding to the equilibrium denaturation profiles in Figure 3A. The standard errors of the fits are shown.
The Loop-Inserted Conformation Is Less Stable in the Mutant than in Wild-Type
Disruption of the integrity of β-sheet A by the introduction of a mid-strand proline might be expected to destabilize the loop-inserted conformation of alpha-1 antitrypsin. This hyperstable, thermodynamically preferred state is achieved after cleavage of the RCL by a protease or partial misfolding to the latent form; additionally, the prevailing models of polymerization predicate a loop-inserted state for the repeating subunit. Protein, cleaved with Staphylococcus aureus protease V8 (35), was incubated in increasing concentrations of guanidinium hydrochloride for 2 hours and was resolved by PAGE using a 6 M urea gel. This system preserved intact cleaved alpha-1 antitrypsin but prevented refolding of denatured protein on the gel. The resulting profile showed a transition for ATA336P from folded to unfolded at 5.5 M guanidinium hydrochloride, a concentration approximately 0.5 M lower than that required to unfold cleaved ATM and ATZ (Figure 3B). Thus, a destabilized β-sheet A manifests a decreased thermodynamic stability of the six-stranded form.
The Folding Efficiency of Z Alpha-1 Antitrypsin Is Lower than That of the Ala336Pro Variant
The alpha-1 antitrypsin variants were subjected to snap-refolding by a 200-fold dilution from a 10 mg/ml stock and visualized by nondenaturing PAGE (Figure 3C, top panel). The gels showed development of three conformations: monomer, a slower-migrating band reflecting the intermediate, and an oligomeric species likely to be dimer. Densitometry revealed the recovery of material to be incomplete on refolding, with 87.5, 72.8, and 44.7% activity regained for ATM, ATA336P, and ATZ, respectively (Figure 3C, lower panel). ATA336P was therefore able to fold almost as well as ATM, in contrast to ATZ. Upon refolding, ATA336P populated the intermediate state more than ATM but less than ATZ, whereas it formed the oligomeric state to a greater extent than either.
These observations, combined with the character of the intermediate in the presence of denaturant, indicate that Glu342 is foremost a “gatekeeper” amino acid that is of particular importance in the folding pathway. However, it is less important in preventing formation of ordered polymers associated with refolding. Conversely, the residues of the shutter are required for native stability and function, and the Ala336Pro mutation perturbs this to allow self-association after substantial refolding.
Ala336Pro Allows the Polymerization Intermediate to Form More Readily than the Z Mutation
Polymerization of alpha-1 antitrypsin can be induced by heat, yielding polymers that share an epitope with ex vivo material (9). Thermal challenge represents a tool for investigating the effect of a mutation on the polymerization pathway, which observes a progression from monomer native state (M) to a polymerization-prone monomeric intermediate (M*) that oligomerizes to form hyperstable polymers (P) (14, 17):
The native and intermediate states are considerably less thermodynamically stable than the polymeric form, to the extent that the polymerization step is essentially irreversible; consequently, techniques that interrogate this pathway observe a partially kinetic rather than an equilibrium process. Thermal denaturation experiments using SYPRO Orange involve an incremental increase in temperature (typically 1°C/min) and provide a measure of the stability of the native state of a protein, reported as the temperature at which a 50% “unfolding” is observed (TM). For alpha-1 antitrypsin, this reports the unimolecular conversion from the native state to the polymerization intermediate (21).
This assay showed a general lack of reversibility when temperature was decreased after a period of heating (Figure E1D). This reflected an inability of the system to achieve equilibrium, an effect that could be accounted for by varying the rate of temperature increase (36). Accordingly, the three variants were heated at increments of 0.5, 0.9, 1.4, 2.4, 3.2, and 9.0°C/min (rates determined a posteriori by measurement within the instrument during the experiment). The resulting Tm values were indeed influenced by the temperature ramp, confirming that the results are influenced by kinetic, rather than equilibrium, processes (Figure 4A, left panel). The apparent height of the energy barrier to intermediate formation, Eact,app, was derived from the slopes of the regressions (Figure 4A, right panel). ATZ was found to have a lower kinetic barrier (by 160 ± 45 kJ/mol) to intermediate formation than ATM, qualitatively consistent with results obtained for the rate of unfolding in denaturant (34), and for ATA336P this was lower still (by 280 ± 40 kJ/mol). Thus, ATA336P is able to convert to the intermediate from the native state (M→M*) more readily than ATZ or ATM.
Ala336Pro Increases the Rate of Polymerization
FRET (Förster resonance energy transfer) can be used to monitor the heat-induced incorporation of alpha-1 antitrypsin monomers into a growing polymer chain (17, 21, 22). The half-time of fluorescence increase was determined at a range of temperatures between 50 and 60°C (Figure 4B, left panel). From a comparison of rates with ATM and ATZ on an Årrhenius plot (Figure 4B, right panel), a downward shift was evident for ATA336P. This reflects a considerably faster polymerization at all temperatures surveyed. The regression line permitted interpolation of a half-time at the median temperature of 55°C, at which ATZ was found to polymerize 3.6 times and ATA336P 21 times more quickly than ATM (Figure 4C, left panel).
Ala336Pro Has Specific Effects on the Polymerization Mechanism
The slopes of the regression lines on the Årrhenius plot provide an indication of the energy barrier to oligomerization (M*+M*→ P) (17, 21). The values were found to be comparable for ATM and ATZ, but that of ATA336P was considerably lower (Figure 4C, right panel). Thus, in contrast to ATZ, this mutation has effects on both phases of polymerization (M→M* and M*+ M*→P).
We have previously reported a stability–polymerization profile that reflects the consensus relationship between the rate of polymerization and the effects on native state stability (21). Deviations from this trend are diagnostic for specific effects of a mutation on the polymerization mechanism itself. Under the conditions of these experiments, this was found to be the case for both ATZ and ATA336P with respect to ATM (Figure 4D).
Discussion
Here we describe a novel mutant of alpha-1 antitrypsin in a homozygous individual who is healthy and has no personal or family medical history suggestive of alpha-1 antitrypsin deficiency. The comprehensive biophysical and biochemical characterization of the novel ATA336P variant allows detailed comparison with the classic ATZ variant that is associated with severe lung and liver disease. This can be correlated with clinical chemistry findings to inform her ongoing management and investigation and to provide genetic counseling regarding the implications for her children; they are obligate carriers of at least one copy of the novel allele. The index individual has a profound functional deficiency of circulating ATA336P due to multiple factors; in addition to reduced circulating levels of total alpha-1 antitrypsin in a range conventionally associated with moderate clinical significance, the protein is predominantly polymeric, and the native monomer is far less effective as an antiprotease relative to the wild-type protein ATM. The resultant loss-of-function is of similar severity to that observed in ATZ (PiZZ) homozygotes.
Such “experiments of nature” can also inform upon details of the mechanisms by which alpha-1 antitrypsin inhibits lung proteases in health and is subject to misfolding and polymerization in disease. The inhibitory mechanism involves translocation of a covalently bound protease by around 70 Å to the opposite pole of the molecule as the RCL becomes incorporated as an additional strand within β-sheet A (s4A) (37). The Glu342Lys mutation in Z antitrypsin is situated in the “breach” region of β-sheet A (Figure 1A), which is the point of first incorporation for the RCL. Although the loss of the associated salt bridge has minimal consequences for the thermodynamic stability of the molecule (34), it is known that the result is a less efficient protease inhibitor than the wild-type protein reflected by a reduction in activity of around 30% (38). This suggests a defect in the mechanism of conformational change. Additionally, a decrease in the rate of association is observed, indicative of a nonnative RCL presentation (13). The more pronounced perturbation of the inhibitory behavior by the Ala336Pro mutation (an SI of 2.7 and an SI-adjusted kass of 2.8 × 105 M/s) similarly reflects the effects on β-sheet A and the conformation of the RCL, respectively, despite a location for the mutation that is six amino acids N-terminal to that of the Z allele. During the inhibitory process, helix F and the post-helix F loop represent a barrier that undergoes deformation to accommodate the translocating protease; these elements lie in the vicinity of Ala336 (39, 40). The thermodynamic destabilization of the inserted state (Figure 3B) due to “edge-strand-effects” (Figure 1A, right panels) may reduce the energetic impetus that drives RCL insertion. This would provide an opportunity for the enzyme to become deacylated and escape the covalent complex.
Characterizing the folding of alpha-1 antitrypsin to a metastable native state, whether as a purified polypeptide or within cells, and misfolding in disease are important research goals. Comparative refolding and equilibrium denaturant studies in ATM, ATZ, and ATA336P further inform on the specifics of the process. Our observations suggest that Glu342 acts as a “gatekeeper” residue, guiding the correct placement of the top of s5A in the folding intermediate, but that the nature of the residue at this position becomes far less important in thermodynamic stabilization of the native state. The central portion of s5A, in contrast, plays a more pronounced role in the native state than the intermediate state, consistent with experiments using hydrogen-deuterium exchange that show this region to be in a slow exchange regimen, reflecting low conformational lability in ATM (41).
The combination of low circulating alpha-1 antitrypsin levels and the observation that polymers of ATA336P were present in the plasma of the affected individual indicated that the novel mutation was polymerogenic. This was confirmed by characterization of the purified protein: reduced barriers to both intermediate formation and oligomerization were evident, rendering it more polymerization prone than either ATZ or ATM. Although the thermodynamic stability of the native state of ATZ is comparable to ATM, with differences residing in the rate of interchange between native and unfolding intermediate, equilibrium denaturant and thermal unfolding showed the native and cleaved state of ATA336P to be less stable than either (Figures 3B, 3A, and 4A, left). However, both ATA336P and ATZ predispose to polymerization by additional effects beyond global destabilization of the fold. They therefore act by specifically promoting conformational changes required for polymerization. The finding that folding and polymerization are differentially affected by Ala336Pro and Glu342Lys mutations indicates that the overall degrees of misfolding and polymerization are not directly related in alpha-1 antitrypsin deficiency variants.
Challenge of monomeric alpha-1 antitrypsin by heat or denaturant results in polymers with different electrophoretic, immunological, and structural characteristics (42, 43), but only the former share a conformational epitope with ex vivo pathological polymers (9, 42). It is likely that this difference is also manifest in intermediate ensembles induced by the two approaches. Indeed, the heat-induced alpha-1 antitrypsin intermediate shows evidence for a more compact state than that observed in 1 M guanidinium hydrochloride (41, 42, 44). However, regional differences in s5A behavior are similar in both the denaturant-mediated and heat-induced polymerization (Table 2; Figure 4C, right). The Ala336Pro mutation influences stability of the denaturant-induced intermediate against further unfolding and enhances the propensity of the thermal intermediate or refolded material to oligomerize. In contrast, the Glu342Lys mutation does not influence these steps.
The highly polymerogenic nature of the ATA336P mutation clearly renders the homozygous individual more vulnerable to lung disease through loss-of-function. Regarding the liver disease, our detailed characterization of this protein allows us to place it into a class of mutants that exhibit similar properties. Specifically, its high propensity to polymerize, in common with neighboring shutter domain mutants associated with liver disease (45), indicates this individual should continue to be monitored for evidence of liver dysfunction. Thus, insights from basic science, closely related to clinical context, are now guiding the personalized management of the ATA336P alpha-1 antitrypsin homozygote.
Acknowledgments
Acknowledgments
The authors thank the staff at the London Alpha-1 Antitrypsin Service for their help with this study.
Footnotes
This work was supported by the Medical Research Council (UK), by GlaxoSmithKline (I.H.), by NIHR Biomedical Research Centre at UCL Hospitals NHS Foundation Trust and UCL (A.D.S. and D.A.L.), by a Smith College “Praxis: The Liberal Arts at Work” summer internship (G.L.R.-M.), and by a Marie Curie Fellowship (N.M.-S.).
Author Contributions: I.H., J.A.I., J.R.H., B.G., and D.A.L. conceived and designed the study. I.H., J.A.I., A.D.S., L.D., G.L.R.-M., and N.M.-S. performed experiments and data acquisition. I.H., J.A.I., L.D., J.R.H., B.G., and D.A.L. analyzed and interpreted data. I.H., J.A.I., B.G., and D.A.L. wrote the manuscript. All authors edited and approved the manuscript.
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Originally Published in Press as DOI: 10.1165/rcmb.2015-0154OC on June 19, 2015
Author disclosures are available with the text of this article at www.atsjournals.org.
References
- 1.Zaimidou S, van Baal S, Smith TD, Mitropoulos K, Ljujic M, Radojkovic D, Cotton RG, Patrinos GP. A1ATVar: a relational database of human SERPINA1 gene variants leading to α1-antitrypsin deficiency and application of the VariVis software. Hum Mutat. 2009;30:308–313. doi: 10.1002/humu.20857. [DOI] [PubMed] [Google Scholar]
- 2.Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest. 1991;100:703–708. doi: 10.1378/chest.100.3.703. [DOI] [PubMed] [Google Scholar]
- 3.Allan PC, Harley RA, Talamo RC. A new method for determination of alpha-1-antitrypsin phenotype using isoelectric focusing on polyacrylamide gel slabs. Am J Clin Pathol. 1974;62:732–739. doi: 10.1093/ajcp/62.6.732. [DOI] [PubMed] [Google Scholar]
- 4.Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294:1316–1321. doi: 10.1056/NEJM197606102942404. [DOI] [PubMed] [Google Scholar]
- 5.Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJ, Jr, Campbell EJ. Alpha-1-antitrypsin deficiency: high prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989;140:961–966. doi: 10.1164/ajrccm/140.4.961. [DOI] [PubMed] [Google Scholar]
- 6.Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, α1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem. 1996;271:22791–22795. doi: 10.1074/jbc.271.37.22791. [DOI] [PubMed] [Google Scholar]
- 7.Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357:605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
- 8.Tan L, Dickens JA, Demeo DL, Miranda E, Perez J, Rashid ST, Day J, Ordonez A, Marciniak SJ, Haq I, et al. Circulating polymers in α1-antitrypsin deficiency. Eur Respir J. 2014;43:1501–1504. doi: 10.1183/09031936.00111213. [DOI] [PubMed] [Google Scholar]
- 9.Miranda E, Perez J, Ekeowa UI, Hadzic N, Kalsheker N, Gooptu B, Portmann B, Belorgey D, Hill M, Chambers S, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with α1-antitrypsin deficiency. Hepatology. 2010;52:1078–1088. doi: 10.1002/hep.23760. [DOI] [PubMed] [Google Scholar]
- 10.Mahadeva R, Lomas DA. Alpha1-antitrypsin deficiency, cirrhosis and emphysema. Thorax. 1998;53:501–505. doi: 10.1136/thx.53.6.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z α1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol. 2011;45:261–269. doi: 10.1165/rcmb.2010-0328OC. [DOI] [PubMed] [Google Scholar]
- 12.Irving JA, Pike RN, Lesk AM, Whisstock JC. Phylogeny of the serpin superfamily implications of patterns of amino acid conservation for structure and function. Genome Res. 2000;10:1845–1864. doi: 10.1101/gr.gr-1478r. [DOI] [PubMed] [Google Scholar]
- 13.Lomas DA, Evans DL, Stone SR, Chang WS, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry. 1993;32:500–508. doi: 10.1021/bi00053a014. [DOI] [PubMed] [Google Scholar]
- 14.Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA. A kinetic mechanism for the polymerization of alpha1-antitrypsin. J Biol Chem. 1999;274:9548–9555. doi: 10.1074/jbc.274.14.9548. [DOI] [PubMed] [Google Scholar]
- 15.Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675. doi: 10.1038/nmeth.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- 17.Haq I, Irving JA, Faull SV, Dickens JA, Ordonez A, Belorgey D, Gooptu B, Lomas DA. Reactive centre loop mutants of alpha-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway. Biosci Rep. 2013;33:e00046. doi: 10.1042/BSR20130038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Elliott PR, Abrahams JP, Lomas DA. Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol. 1998;275:419–425. doi: 10.1006/jmbi.1997.1458. [DOI] [PubMed] [Google Scholar]
- 19.Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5. [DOI] [PubMed] [Google Scholar]
- 20.Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781–1802. doi: 10.1002/jcc.20289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Irving JA, Haq I, Dickens JA, Faull SV, Lomas DA. Altered native stability is the dominant basis for susceptibility of α1-antitrypsin mutants to polymerization. Biochem J. 2014;460:103–115. doi: 10.1042/BJ20131650. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Irving JA, Miranda E, Haq I, Perez J, Kotov VR, Faull SV, Motamedi-Shad N, Lomas DA. An antibody raised against a pathogenic serpin variant induces mutant-like behaviour in the wild-type protein. Biochem J. 2015;461:99–108. doi: 10.1042/BJ20141569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Barrick D, Baldwin RL. Three-state analysis of sperm whale apomyoglobin folding. Biochemistry. 1993;32:3790–3796. doi: 10.1021/bi00065a035. [DOI] [PubMed] [Google Scholar]
- 24.Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol. 1995;2:96–113. doi: 10.1038/nsb0295-96. [DOI] [PubMed] [Google Scholar]
- 25.Whisstock JC, Skinner R, Carrell RW, Lesk AM. Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin. J Mol Biol. 2000;295:651–665. doi: 10.1006/jmbi.1999.3375. [DOI] [PubMed] [Google Scholar]
- 26.Kwon KS, Kim J, Shin HS, Yu MH. Single amino acid substitutions of alpha 1-antitrypsin that confer enhancement in thermal stability. J Biol Chem. 1994;269:9627–9631. [PubMed] [Google Scholar]
- 27.Lomas DA, Finch JT, Seyama K, Nukiwa T, Carrell RW. Alpha 1-antitrypsin Siiyama (Ser53→Phe): further evidence for intracellular loop-sheet polymerization. J Biol Chem. 1993;268:15333–15335. [PubMed] [Google Scholar]
- 28.Lomas D, Elliott P, Sidhar S, Foreman R, Finch J, Cox D, Whisstock J, Carrell R. α1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerization. J Biol Chem. 1995;270:16864–16870. doi: 10.1074/jbc.270.28.16864. [DOI] [PubMed] [Google Scholar]
- 29.Tew DJ, Bottomley SP. Probing the equilibrium denaturation of the serpin alpha(1)-antitrypsin with single tryptophan mutants; evidence for structure in the urea unfolded state. J Mol Biol. 2001;313:1161–1169. doi: 10.1006/jmbi.2001.5104. [DOI] [PubMed] [Google Scholar]
- 30.Knaupp AS, Bottomley SP. Structural change in beta-sheet A of Z alpha(1)-antitrypsin is responsible for accelerated polymerization and disease. J Mol Biol. 2011;413:888–898. doi: 10.1016/j.jmb.2011.09.013. [DOI] [PubMed] [Google Scholar]
- 31.James EL, Whisstock JC, Gore MG, Bottomley SP. Probing the unfolding pathway of alpha1-antitrypsin. J Biol Chem. 1999;274:9482–9488. doi: 10.1074/jbc.274.14.9482. [DOI] [PubMed] [Google Scholar]
- 32.MacArthur MW, Thornton JM. Influence of proline residues on protein conformation. J Mol Biol. 1991;218:397–412. doi: 10.1016/0022-2836(91)90721-h. [DOI] [PubMed] [Google Scholar]
- 33.Hughes VA, Meklemburg R, Bottomley SP, Wintrode PL. The Z mutation alters the global structural dynamics of α1-antitrypsin. PLoS One. 2014;9:e102617. doi: 10.1371/journal.pone.0102617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Knaupp AS, Levina V, Robertson AL, Pearce MC, Bottomley SP. Kinetic instability of the serpin Z α1-antitrypsin promotes aggregation. J Mol Biol. 2010;396:375–383. doi: 10.1016/j.jmb.2009.11.048. [DOI] [PubMed] [Google Scholar]
- 35.Lomas DA, Elliott PR, Chang WS, Wardell MR, Carrell RW. Preparation and characterization of latent alpha 1-antitrypsin. J Biol Chem. 1995;270:5282–5288. doi: 10.1074/jbc.270.10.5282. [DOI] [PubMed] [Google Scholar]
- 36.Sánchez-Ruiz JM, López-Lacomba JL, Cortijo M, Mateo PL. Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin. Biochemistry. 1988;27:1648–1652. doi: 10.1021/bi00405a039. [DOI] [PubMed] [Google Scholar]
- 37.Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000;407:923–926. doi: 10.1038/35038119. [DOI] [PubMed] [Google Scholar]
- 38.Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80:1366–1374. doi: 10.1172/JCI113214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Cabrita LD, Dai W, Bottomley SP. Different conformational changes within the F-helix occur during serpin folding, polymerization, and proteinase inhibition. Biochemistry. 2004;43:9834–9839. doi: 10.1021/bi0491346. [DOI] [PubMed] [Google Scholar]
- 40.Maddur AA, Swanson R, Izaguirre G, Gettins PGW, Olson ST. Kinetic intermediates en route to the final serpin-protease complex: studies of complexes of α1-protease inhibitor with trypsin. J Biol Chem. 2013;288:32020–32035. doi: 10.1074/jbc.M113.510990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Tsutsui Y, Dela Cruz R, Wintrode PL. Folding mechanism of the metastable serpin α1-antitrypsin. Proc Natl Acad Sci USA. 2012;109:4467–4472. doi: 10.1073/pnas.1109125109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Ekeowa UI, Freeke J, Miranda E, Gooptu B, Bush MF, Perez J, Teckman J, Robinson CV, Lomas DA. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci USA. 2010;107:17146–17151. doi: 10.1073/pnas.1004785107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yamasaki M, Li W, Johnson DJ, Huntington JA. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature. 2008;455:1255–1258. doi: 10.1038/nature07394. [DOI] [PubMed] [Google Scholar]
- 44.Tsutsui Y, Kuri B, Sengupta T, Wintrode PL. The structural basis of serpin polymerization studied by hydrogen/deuterium exchange and mass spectrometry. J Biol Chem. 2008;283:30804–30811. doi: 10.1074/jbc.M804048200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Janciauskiene S, Eriksson S, Callea F, Mallya M, Zhou A, Seyama K, Hata S, Lomas D. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology. 2004;40:1203–1210. doi: 10.1002/hep.20451. [DOI] [PubMed] [Google Scholar]
- 46.DeLano W. New York, NY: Schrodinger; 2010. The PyMOL molecular graphics system, Version 1.3r1. [Google Scholar]
- 47.Costas M, Rodriguez-Larrea D, De Maria L, Borchert TV, Gomez-Puyou A, Sanchez-Ruiz JM. Between-species variation in the kinetic stability of TIM proteins linked to solvation-barrier free energies. J Mol Biol. 2009;385:924–937. doi: 10.1016/j.jmb.2008.10.056. [DOI] [PubMed] [Google Scholar]